FDA has faced multiple headlines in reference to their handling of
Moderna's application for the review of their new
mRNA flu vaccine. Initially, the agency rejected the application, causing a stir in the biotech market and leading to a decrease in shares for Moderna. The decision was then reversed, with FDA agreeing to review the vaccine. This has been a point of contention causing
valuation risks mount for Moderna. Meanwhile, Moderna has been working on settling
patent lawsuits, with figures reaching up to $2.25 billion.
EMA has recommended approval of a combined mRNA vaccine for flu and COVID, likely increasing interest in Moderna's technology and its shares. There have also been studies indicating that Moderna's mRNA COVID-19 vaccine does not provide a myocarditis signal. Despite the numerous hurdles, Moderna continues to pursuit approval for their flu shot. Amid all these, Moderna has announced a $950M settlement for an mRNA jab litigation and expanded mRNA manufacturing in the US.
Moderna MRNA News Analytics from Tue, 20 May 2025 07:00:00 GMT to Sat, 28 Mar 2026 01:11:49 GMT -
Rating 4
- Innovation 7
- Information 8
- Rumor -5
